What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis
Purpose The optimum systemic therapies for advanced/metastatic renal cell carcinoma (RCC) of favourable, intermediate and poor risk have not been established. We aimed to compare and rank the effects associated with systemic therapies in the first-line setting.Methods We searched PubMed, Cochrane da...
Main Authors: | Guanghui Cao, Xiaoqiang Wu, Zhiwei Wang, Xiangyong Tian, Chan Zhang, Xuan Wu, Haotian Zhang, Gaopeng Jing, Tianzhong Yan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-08-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/10/8/e034626.full |
Similar Items
-
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysisResearch in context
by: Junpeng Wang, et al.
Published: (2019-09-01) -
Expression Profiling of Exosomal miRNAs Derived from the Peripheral Blood of Kidney Recipients with DGF Using High-Throughput Sequencing
by: Junpeng Wang, et al.
Published: (2019-01-01) -
Optimum structural modification with respect to dynamic behaviour
by: Jonas, Stephan
Published: (2007) -
Learning echocardiography- what are the challenges and what may favour learning? A qualitative study
by: Anna Dieden, et al.
Published: (2019-06-01) -
Species traits, patch turnover and successional dynamics: when does intermediate disturbance favour metapopulation occupancy?
by: Frederico Mestre, et al.
Published: (2020-01-01)